Date: 2013-10-03
Type of information: Plant acquisition
Acquired company: Arixtra and Fraxiparine/Fraxodi brands and GSK manufacturing site
Acquiring company: Aspen Global Incorporated (South Africa)
Amount: £700 million (€838,7 million)
Terms: * On September 30, 2013, Aspen Global Incorporated, a wholly owned subsidiary of Aspen, announced today that it will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands and business worldwide, except in China, Pakistan and Indiaas well as a specialised sterile production site which manufactures the brands at Notre Dame de Bondeville, France for £700 million in cash, of which £100 million relates to inventory. Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production. Subject to regulatory approvals, it is expected that the majority of commercial operations will transfer to Aspen by the end of the year with the remainder, along with the Site, to follow in the first half of 2014.
Details: * On December 31, 2013, GSK has announced that it has completed the previously announced divestment of its thrombosis brands, Arixtra™ and Fraxiparine™ to the Aspen Group for £700 million, following regulatory approval of the transaction. The majority of commercial operations will formally transfer to Aspen on 1 January 2014 with the remainder, along with the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.
Related:
